KJKristin Johnson

Kristin Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristin Johnson has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification

    by Vilma Landfors Andersson, Kristin Johnson, Ida Skarping

    Background: Heterogeneous treatment response, characterized by simultaneous regression of some lesions and progression of others within the same patient, is increasingly recognized in metastatic breast cancer (mBC) and may reflect biological heterogeneity. However, this response pattern is not captured by current response assessment frameworks. We aimed to determine the prevalence of heterogeneous treatment response on FDG-PET and mixed response on CT during mBC systemic therapy. Methods: This retrospective study included 51 female patients with mBC, treated between November 2017 and November 2025, each undergoing ≥ 2 FDG-PET/CT scans. Response was assessed according to RECIST 1.1 (CT) and PERCIST (FDG-PET), with using study‑specific definitions for heterogeneous/mixed response informed by literature. Results: Heterogeneous metabolic response was observed in 30% of all follow‑up FDG‑PET examinations (40/132). These examinations accounted for 60% (40/67) of the scans classified as progressive metabolic disease (PMD) according to PERCIST. Among CT-examinations, 65 of 141 (46%) follow-up examinations had measurable disease; none of these scans (0/65, 0%) fulfilled the mixed response criteria. Conclusion: In this real-world cohort of mBC undergoing systemic therapy, FDG-PET identified heterogeneous treatment response in a substantial proportion of patients; however, under current PERCIST criteria, these cases were uniformly classified as PMD. In contrast, using RECIST-inspired criteria, CT did not classify any patient as mixed response. These findings suggest that existing frameworks may not fully capture intra-patient response heterogeneity. As heterogeneous response is not an established PERCIST response category, further work is needed to determine how such patterns should be defined and incorporated into future response assessment frameworks. Clinical trial number: Not applicable.

  • Open Access

    UNRAVELLING A HIDDEN SUBTYPE: MULTIOMICS REVEAL PSORIASIS-LIKE SIGNATURE WITH SURGICAL RELEVANCE IN A SUBSET OF PERIANAL FISTULIZING CROHN'S DISEASE

    by Saeed Abdurahiman, João Sabino, Sare Verstockt, Kristin Johnson, Lorenzo Giorio, Kaline Arnauts, Caitlin Van de Perre, Clara Caenepeel, Matthias Lenfant, Marc Ferrante, et al.

    Background and aims: Perianal fistulizing Crohn's disease (pCD) affects 20% of patients with Crohn's disease (CD) and severely impacts quality of life. Current therapies fail to provide sustained relief, and the molecular underpinnings of pCD remain poorly understood. This study aimed to elucidate the molecular landscape of perianal fistulas through multiomic profiling. Methods: Paired fistula-tract and adjacent rectal mucosal biopsies were collected from 63 patients (48 with pCD, 15 with cryptoglandular fistula [CPTGL]). Longitudinal sampling generated 101 unique molecular profiles, comprising of both RNA sequencing (RNA-seq) and 16S rRNA sequencing from both tissue sites, followed by integrative multiomics and gene network analyses. Results: Unsupervised clustering revealed three patient clusters primarily defined by host gene expression, with minimal contribution from microbial profiles. Fistulae in clusters 1 and 2 showed strong immune activation and epithelial-mesenchymal transition (EMT). In contrast, cluster 3 fistulae displayed keratinization and metabolic reprogramming resembling psoriatic skin, together with reduced JAK-STAT signalling. Cluster 3 was enriched for patients classified as TOpClass:2a, who are more suitable for surgical repair (p = 0.02). Conversely, cluster 2, characterized by rectal keratinization and EMT in both fistula and rectum, showed the highest MRI inflammatory-mass score (p = 0.02) and a greater risk of subsequent ileostomy (Kaplan-Meier; p = 0.008). An independent RNAseq dataset validated the keratinization signature in a subset of pCD fistulae. Conclusion: Integrated multiomic analysis identified distinct molecular subtypes of pCD with surgical and therapeutic relevance. These findings refine the molecular understanding of pCD and support a precision medicine approach.

  • Open Access

    Assessing mammographic density change within individuals across screening rounds using deep learning–based software

    by Jakob Olinder, Daniel Förnvik, Victor Dahlblom, Viktor Lu, Anna Åkesson, Kristin Johnson, Sophia Zackrisson

    PurposeThe purposes are to evaluate the change in mammographic density within individuals across screening rounds using automatic density software, to evaluate whether a change in breast density is associated with a future breast cancer diagnosis, and to provide insight into breast density evolution.ApproachMammographic breast density was analyzed in women screened in Malmö, Sweden, between 2010 and 2015 who had undergone at least two consecutive screening rounds <30 months apart. The volumetric and area-based densities were measured with deep learning–based software and fully automated software, respectively. The change in volumetric breast density percentage (VBD%) between two consecutive screening examinations was determined. Multiple linear regression was used to investigate the association between VBD% change in percentage points and future breast cancer, as well as the initial VBD%, adjusting for age group and the time between examinations. Examinations with potential positioning issues were removed in a sensitivity analysis.ResultsIn 26,056 included women, the mean VBD% decreased from 10.7% [95% confidence interval (CI) 10.6 to 10.8] to 10.3% (95% CI: 10.2 to 10.3) (p<0.001) between the two examinations. The decline in VBD% was more pronounced in women with initially denser breasts (adjusted β=−0.10, p<0.001) and less pronounced in women with a future breast cancer diagnosis (adjusted β=0.16, p=0.02).ConclusionsThe demonstrated density changes over time support the potential of using breast density change in risk assessment tools and provide insights for future risk-based screening.


  • Assessing change in mammographic density within individuals across screening rounds using an artificial intelligence software

    by Jakob Olinder, Daniel Förnvik, Kristin Johnson, Sophia Zackrisson

    In potential individualized breast density-based breast cancer screening programs, risk-based models and when generating realistic digital breast phantoms, it is important to understand the normal changes in breast density. Breast density in 26 182 women in two consecutive screening rounds was retrospectively assessed with a commercial AI software. A small but significant decrease in breast density between two screening rounds was seen. The decline in breast density was more pronounced among women with denser breasts.


  • Open Access

    Cancers not detected in one-view breast tomosynthesis screening—characteristics and reasons for non-detection

    by Kristin Johnson, Debra M. Ikeda, Ingvar Andersson, Sophia Zackrisson

    Objectives: Limited understanding exists regarding non-detected cancers in digital breast tomosynthesis (DBT) screening. This study aims to classify non-detected cancers into true or false negatives, compare them with true positives, and analyze reasons for non-detection. Materials and methods: Conducted between 2010 and 2015, the prospective single-center Malmö Breast Tomosynthesis Screening Trial (MBTST) compared one-view DBT and two-view digital mammography (DM). Cancers not detected by DBT, i.e., interval cancers, those detected in the next screening round, and those only identified by DM, underwent a retrospective informed review by in total four breast radiologists. Reviewers classified cancers into true negative, false negative, or non-visible based on both DBT and DM findings and assessed radiographic appearances at screening and diagnosis, breast density, and reasons for non-detection. Statistics included the Pearson X 2 test. Results: In total, 89 cancers were not detected with DBT in the MBTST; eight cancers were solely in the DM reading mode, 59 during subsequent DM screening rounds, and 22 interval cancers. The proportion of cancers classified as false negative was 25% (22/89) based on DBT, compared with 18% (14/81) based on DM screening. The primary reason for false negatives was normal-appearing density, 50% (11/22). False negatives exhibited lower rates of high breast density, 36% (8/22), compared with true positives, 61% (78/129), p = 0.04, and spiculated densities were less frequent in false negatives, 41% (9/22) compared with true positives, 68% (88/129), p = 0.01. Conclusion: False negatives in one-view DBT screening commonly presented with spiculated features, but less frequently than true positives, and were missed or misinterpreted due to benign appearances. Key Points: Question Cancers not detected in digital breast tomosynthesis screening, including false negatives, remain partly unexplored. Findings The most common reason behind false-negative cancers in a large screening trial was a normal-appearing density. Clinical relevance Recognizing the factors contributing to false negative findings in digital breast tomosynthesis screening is essential to further improve cancer detection. Graphical

  • Open Access

    Our journey toward implementation of digital breast tomosynthesis in breast cancer screening: the Malmö Breast Tomosynthesis Screening Project

    by Anders Tingberg, Victor Dahlblom, Magnus Dustler, Daniel Förnvik, Kristin Johnson, Pontus Timberg, Sophia Zackrisson

    Mammography is a particularly difficult radiological field and requires highly specialized radiologists to achieve acceptable levels of detection and classification of breast cancer without excessive recalls. A prerequisite is therefore images of the highest possible diagnostic quality and acquired at the lowest possible radiation dose because the breast is an organ that is relatively sensitive to radiation,1 and most of the women in the screening population are healthy. Digital mammography (DM) is still the gold standard breast cancer screening method in most of Europe, with a sensitivity claimed to be around 80%.2 When we in our research group first learned about digital breast tomosynthesis (DBT) during a presentation at the SPIE Medical Imaging symposium in 2004,3 it was obvious that this new technique would become a game changer in breast cancer screening.4 Even non-radiologists were able to detect breast cancers in selected cases, cancers that were missed in the corresponding DM image.


  • Assessing Digital Breast Tomosynthesis Impact on Early Cancer Detection: Insights from Consecutive Screening

    by Annika Jögi, Kristin Johnson, Sofia Wittgren, Victor Sundgren, Hanna Tomic, Jakob Olinder, Anna Åkesson, Ingvar Andersson, Sophia Zackrisson, Predrag R. Bakic

    Analysis of the Malmö Breast Tomosynthesis Screening Trial revealed lower cancer detection rates and invasive cancers after tomosynthesis, suggesting enhanced early detection potential, particularly for luminal A–like cancers.


  • Open Access

    False-positive recalls in the prospective Malmö Breast Tomosynthesis Screening Trial

    by Kristin Johnson, Jakob Olinder, Aldana Rosso, Ingvar Andersson, Kristina Lång, Sophia Zackrisson

    Objectives: To evaluate the total number of false-positive recalls, including radiographic appearances and false-positive biopsies, in the Malmö Breast Tomosynthesis Screening Trial (MBTST). Methods: The prospective, population-based MBTST, with 14,848 participating women, was designed to compare one-view digital breast tomosynthesis (DBT) to two-view digital mammography (DM) in breast cancer screening. False-positive recall rates, radiographic appearances, and biopsy rates were analyzed. Comparisons were made between DBT, DM, and DBT + DM, both in total and in trial year 1 compared to trial years 2 to 5, with numbers, percentages, and 95% confidence intervals (CI). Results: The false-positive recall rate was higher with DBT, 1.6% (95% CI 1.4; 1.8), compared to screening with DM, 0.8% (95% CI 0.7; 1.0). The proportion of the radiographic appearance of stellate distortion was 37.3% (91/244) with DBT, compared to 24.0% (29/121) with DM. The false-positive recall rate with DBT during trial year 1 was 2.6% (95% CI 1.8; 3.5), then stabilized at 1.5% (95% CI 1.3; 1.8) during trial years 2 to 5. The percentage of stellate distortion with DBT was 50% (19/38) trial year 1 compared to 35.0% (72/206) trial years 2 to 5. Conclusions: The higher false-positive recall rate with DBT compared to DM was mainly due to an increased detection of stellate findings. The proportion of these findings, as well as the DBT false-positive recall rate, was reduced after the first trial year. Clinical relevance statement: Assessment of false-positive recalls gives information on potential benefits and side effects in DBT screening. Key Points: • The false-positive recall rate in a prospective digital breast tomosynthesis screening trial was higher compared to digital mammography, but still low compared to other trials. • The higher false-positive recall rate with digital breast tomosynthesis was mainly due to an increased detection of stellate findings; the proportion of these findings was reduced after the first trial year.


  • Open Access

    Malmö Breast ImaginG database: objectives and development

    by Victor Dahlblom, Magnus Dustler, Anetta Bolejko, Predrag R. Bakic, Henrik Granberg, Kristin Johnson, Daniel Förnvik, Kristina Lång, Anders Tingberg, Sophia Zackrisson

    PurposeWe describe the design and implementation of the Malmö Breast ImaginG (M-BIG) database, which will support research projects investigating various aspects of current and future breast cancer screening programs. Specifically, M-BIG will provide clinical data to:1.investigate the effect of breast cancer screening on breast cancer prognosis and mortality;2.develop and validate the use of artificial intelligence and machine learning in breast image interpretation; and3.develop and validate image-based radiological breast cancer risk profiles.ApproachThe M-BIG database is intended to include a wide range of digital mammography (DM) and digital breast tomosynthesis (DBT) examinations performed on women at the Mammography Clinic in Malmö, Sweden, from the introduction of DM in 2004 through 2020. Subjects may be included multiple times and for diverse reasons. The image data are linked to extensive clinical, diagnostic, and demographic data from several registries.ResultsTo date, the database contains a total of 451,054 examinations from 104,791 women. During the inclusion period, 95,258 unique women were screened. A total of 19,968 examinations were performed using DBT, whereas the rest used DM.ConclusionsWe describe the design and implementation of the M-BIG database as a representative and accessible medical image database linked to various types of medical data. Work is ongoing to add features and curate the existing data.